X

Trial Profile

Long-term study of K-877

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 28 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pemafibrate (Primary)
Indications Hypertriglyceridaemia; Type 2 diabetes mellitus
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms PROVIDE
Sponsors Kowa

Most Recent Events

03 Jan 2018 Primary endpoint (Percentage change in fasting serum TG level from the baseline at the final evaluation over 24 weeks) has been met, according to results published in the Diabetes Care.
03 Jan 2018 Results assessing the long-term efficacy and safety of pemafibrate treatment for over 24 weeks in patients with type 2 diabetes comorbid with hypertriglyceridemia, were published in the Diabetes Care.
06 Jun 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com